2026 Global: Magnetic Resonance Imaging (Mri) Safe Biopsy Needle Market -Competitive Review (2032) report
Description
The 2026 Global: Magnetic Resonance Imaging (Mri) Safe Biopsy Needle Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Key vendors shaping the MRI-safe biopsy needle landscape include Becton, Dickinson and Company (Franklin Lakes, United States), Boston Scientific (Marlborough, United States), Cook Medical (Bloomington, United States), Medtronic (Dublin, Ireland), and Merit Medical Systems (South Jordan, United States). These firms supply needle platforms used for magnetic resonance imaging‑guided percutaneous sampling, including core biopsy and vacuum‑assisted configurations designed to preserve MRI compatibility and minimize artifact. BD offers a line of biopsy needles and introducer systems compatible with MRI workflows, supporting sampling in breast, liver, and musculoskeletal applications. Boston Scientific extends its interventional portfolio with MRI‑conditional core needles and needle guidance accessories, enabling precise targeting under MRI visualization. Cook Medical provides MRI‑safe needle assemblies and accessories integrated into their biopsy suites, whereas Medtronic markets MRI‑ready biopsy devices within its interventional radiology line, and Merit Medical supplies vacuum‑assisted and core biopsy needles with MRI compatibility. Together, these leaders anchor adoption and regulatory alignment.
Additional crucial players include AngioDynamics (Latham, United States), Hologic (Marlborough, United States), and Stryker (Kalamazoo, United States). AngioDynamics emphasizes interventional access devices and biopsy needles compatible with MRI environments, supporting image-guided sampling in oncology and inflammatory diseases. The company’s MRI‑ready needle platforms integrate with both diagnostic and therapeutic workflows, and its coil and guidance kits enable efficient targeting within clinical MRI suites. Hologic remains a leader in breast imaging and MRI‑guided vacuum‑assisted biopsy, offering MRI‑compatible needles and associated vacuum systems that minimize artifact while preserving tissue integrity. Stryker contributes MRI‑safe biopsy needle families as part of its broader interventional portfolio, emphasizing durability, sterility, and compatibility with MRI protocols in musculoskeletal and oncologic indications. Government and industry collaboration aside, these firms drive cross‑specialty adoption of MRI‑accessible biopsy solutions and help harmonize performance, safety, and regulatory labeling across healthcare systems. Market trajectory will depend on regulatory clarity, physician training, and resilient supply chains to ensure MRI safety across clinical settings worldwide adoption.
Rounding out the ten major entities are B. Braun Medical (Melsungen, Germany) and Terumo (Tokyo, Japan). B. Braun Medical offers biopsy needle sets and MRI‑compatible interventional components as part of its broader line of sterile solutions, with emphasis on procedural safety, corrosion resistance, and compatibility with imaging guidance. Terumo contributes needle technologies and accessories designed for MRI environments, aligning its precision engineering with radiology suites that rely on high-quality visualization and percutaneous sampling. Together, these two manufacturers complete a globally distributed footprint across Europe, Asia, and North America, illustrating the geographic breadth of the MRI‑safe biopsy needle ecosystem. Across the group, clinical stakeholders benefit from diverse option sets, competitive pricing, and collaborative programs to validate MRI performance, ergonomic design, and patient‑centered outcomes in oncologic and non‑oncologic indications. Market trajectory will depend on regulatory clarity, physician training, and resilient supply chains to ensure MRI safety across clinical settings worldwide, enabling adoption.
Key vendors shaping the MRI-safe biopsy needle landscape include Becton, Dickinson and Company (Franklin Lakes, United States), Boston Scientific (Marlborough, United States), Cook Medical (Bloomington, United States), Medtronic (Dublin, Ireland), and Merit Medical Systems (South Jordan, United States). These firms supply needle platforms used for magnetic resonance imaging‑guided percutaneous sampling, including core biopsy and vacuum‑assisted configurations designed to preserve MRI compatibility and minimize artifact. BD offers a line of biopsy needles and introducer systems compatible with MRI workflows, supporting sampling in breast, liver, and musculoskeletal applications. Boston Scientific extends its interventional portfolio with MRI‑conditional core needles and needle guidance accessories, enabling precise targeting under MRI visualization. Cook Medical provides MRI‑safe needle assemblies and accessories integrated into their biopsy suites, whereas Medtronic markets MRI‑ready biopsy devices within its interventional radiology line, and Merit Medical supplies vacuum‑assisted and core biopsy needles with MRI compatibility. Together, these leaders anchor adoption and regulatory alignment.
Additional crucial players include AngioDynamics (Latham, United States), Hologic (Marlborough, United States), and Stryker (Kalamazoo, United States). AngioDynamics emphasizes interventional access devices and biopsy needles compatible with MRI environments, supporting image-guided sampling in oncology and inflammatory diseases. The company’s MRI‑ready needle platforms integrate with both diagnostic and therapeutic workflows, and its coil and guidance kits enable efficient targeting within clinical MRI suites. Hologic remains a leader in breast imaging and MRI‑guided vacuum‑assisted biopsy, offering MRI‑compatible needles and associated vacuum systems that minimize artifact while preserving tissue integrity. Stryker contributes MRI‑safe biopsy needle families as part of its broader interventional portfolio, emphasizing durability, sterility, and compatibility with MRI protocols in musculoskeletal and oncologic indications. Government and industry collaboration aside, these firms drive cross‑specialty adoption of MRI‑accessible biopsy solutions and help harmonize performance, safety, and regulatory labeling across healthcare systems. Market trajectory will depend on regulatory clarity, physician training, and resilient supply chains to ensure MRI safety across clinical settings worldwide adoption.
Rounding out the ten major entities are B. Braun Medical (Melsungen, Germany) and Terumo (Tokyo, Japan). B. Braun Medical offers biopsy needle sets and MRI‑compatible interventional components as part of its broader line of sterile solutions, with emphasis on procedural safety, corrosion resistance, and compatibility with imaging guidance. Terumo contributes needle technologies and accessories designed for MRI environments, aligning its precision engineering with radiology suites that rely on high-quality visualization and percutaneous sampling. Together, these two manufacturers complete a globally distributed footprint across Europe, Asia, and North America, illustrating the geographic breadth of the MRI‑safe biopsy needle ecosystem. Across the group, clinical stakeholders benefit from diverse option sets, competitive pricing, and collaborative programs to validate MRI performance, ergonomic design, and patient‑centered outcomes in oncologic and non‑oncologic indications. Market trajectory will depend on regulatory clarity, physician training, and resilient supply chains to ensure MRI safety across clinical settings worldwide, enabling adoption.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
